Evidence map›Paper›PMID 26061753›Full record

ArticleThe New England journal of medicine2015

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.

Jeanette E Eckel-Passow, Daniel H Lachance, Annette M Molinaro, Kyle M Walsh, Paul A Decker, Hugues Sicotte, Melike Pekmezci, Terri Rice, Matt L Kosel, Ivan V Smirnov and 26 more

Open access · bronzeAbstract read
In one paragraph

Article in The New England journal of medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,205 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,205citing papers in PubMed, 4 pooled it
95.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1,205 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,964 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Independent associations of MGMT promoter methylation and TERT promoter mutation with overall survival in glioblastoma: a single-center retrospective cohort study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  19. Article
  20. Article

1,145 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

36 authors at 6 institutions in 1 country.

Jeanette E Eckel-PassowFrom the Departments of Health Sciences Research (J.E.E.-P., P.A.D., H.S., M.L.K.), Laboratory Medicine and Pathology (D.H.L., G.S., A.A.C., T.M.K., C.E.P., A.R.C., C.H., C.G., R.B.J.), Neurology (D.H.L., B.P.O.), and Oncology (J.C.B.), Mayo Clinic, Rochester, MN; the Departments of Neurological Surgery (A.M.M., K.M.W., T.R., I.V.S., H.M.H., L.S.M., S.Z., A.P., M.S.B., S.M.C., M.D.P., J.K.W., M.R.W.), Epidemiology and Biostatistics (A.M.M., P.M.B., J.W., J.K.W., M.R.W.) and Pathology (M.P., R.M., G.F.R., A.P., T.T.) and the Institute of Human Genetics (J.W., J.K.W., M.R.W.), University of California, San Francisco, and the Bioinformatics Core, Gladstone Institutes (A.R.P.) - all in San Francisco; and the Department of Pathology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York (J.T.H.).
Daniel H Lachance
Annette M Molinaro
Kyle M Walsh
Paul A Decker
Hugues Sicotte
Melike Pekmezci
Terri Rice
Matt L Kosel
Ivan V Smirnov
Gobinda Sarkar
Alissa A Caron
Thomas M Kollmeyer
Corinne E Praska
Anisha R Chada
Chandralekha Halder
Helen M Hansen
Lucie S McCoy
Paige M Bracci
Roxanne Marshall
Shichun Zheng
Gerald F Reis
Alexander R Pico
Brian P O'Neill
Jan C Buckner
Caterina Giannini
Jason T Huse
Arie Perry
Tarik Tihan
Mitchell S Berger
Susan M Chang
Michael D Prados
Joseph Wiemels
John K Wiencke
Margaret R Wrensch
Robert B Jenkins
University of California, San Francisco · USMayo Clinic in Arizona · USNeurological Surgery · USMayo Clinic in Florida · USGladstone Institutes · USMemorial Sloan Kettering Cancer Center · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4M
Targeted MV-CEA as a Potent Antitumor Agent against GBMP50CA108961 · NCI · MAYO CLINIC ROCHESTER · PI O'NEILL, BRIAN PATRICK · 2004 to 2015
$22.5M
GENETIC EPIDEMIOLOGY OF MALIGNANT GLIOMAR01CA052689 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIENCKE, JOHN K., WRENSCH, MARGARET R. · 1991 to 2015
$20.5M
International Case Control Study of Malignant GliomaR01CA139020 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BONDY, MELISSA L. · 2010 to 2015
$16.0M
Training in Molecular& Genetic Epidemiology of CancerR25CA112355 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WITTE, JOHN S. · 2005 to 2018
$6.5M
Biomarkers of survival in glioma epidemiologyR01CA126831 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIENCKE, JOHN K. · 2008 to 2013
$2.5M
Novel Tree-based Statistical Methods for Cancer Risk PredictionR01CA163687 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MOLINARO, ANNETTE M · 2012 to 2015
$1.3M
Identification of 9p and 20q Germline Alterations in Glioblastoma PathogenesisRC1NS068222 · NINDS · MAYO CLINIC ROCHESTER · PI JENKINS, ROBERT B. · 2009 to 2010
$984k
NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA15083NCI NIH HHS P50 CA097257NCI NIH HHS P50CA097257NCI NIH HHS P50 CA108961NCI NIH HHS P50CA108961NCI NIH HHS R01 CA052689NCI NIH HHS R01 CA126831NCI NIH HHS R01CA126831NCI NIH HHS R01 CA139020NCI NIH HHS R01CA139020NCI NIH HHS R01 CA163687NCI NIH HHS R01CA163687NCI NIH HHS R01CA52689NCI NIH HHS R25 CA112355NCI NIH HHS R25CA112355NCRR NIH HHS UL1 RR024131NINDS NIH HHS RC1 NS068222NINDS NIH HHS RC1NS068222Z
6 · The paper itself

Abstract

backgroundThe prediction of clinical behavior, response to therapy, and outcome of infiltrative glioma is challenging. On the basis of previous studies of tumor biology, we defined five glioma molecular groups with the use of three alterations: mutations in the TERT promoter, mutations in IDH, and codeletion of chromosome arms 1p and 19q (1p/19q codeletion). We tested the hypothesis that within groups based on these features, tumors would have similar clinical variables, acquired somatic alterations, and germline variants.

methodsWe scored tumors as negative or positive for each of these markers in 1087 gliomas and compared acquired alterations and patient characteristics among the five primary molecular groups. Using 11,590 controls, we assessed associations between these groups and known glioma germline variants.

resultsAmong 615 grade II or III gliomas, 29% had all three alterations (i.e., were triple-positive), 5% had TERT and IDH mutations, 45% had only IDH mutations, 7% were triple-negative, and 10% had only TERT mutations; 5% had other combinations. Among 472 grade IV gliomas, less than 1% were triple-positive, 2% had TERT and IDH mutations, 7% had only IDH mutations, 17% were triple-negative, and 74% had only TERT mutations. The mean age at diagnosis was lowest (37 years) among patients who had gliomas with only IDH mutations and was highest (59 years) among patients who had gliomas with only TERT mutations. The molecular groups were independently associated with overall survival among patients with grade II or III gliomas but not among patients with grade IV gliomas. The molecular groups were associated with specific germline variants.

conclusionsGliomas were classified into five principal groups on the basis of three tumor markers. The groups had different ages at onset, overall survival, and associations with germline variants, which implies that they are characterized by distinct mechanisms of pathogenesis. (Funded by the National Institutes of Health and others.).

Indexed as

Chromosomes, Human, Pair 1Chromosomes, Human, Pair 19MutationAdultAge of OnsetBiomarkers, TumorDNA Mutational AnalysisDNA, NeoplasmFemaleGerm-Line MutationGliomaHumansIsocitrate DehydrogenaseKaplan-Meier EstimateMaleMiddle AgedBiomarkers, TumorDNA, NeoplasmIDH1 protein, humanIDH2 protein, humanIsocitrate DehydrogenaseTelomeraseTERT protein, human

Identifiers

PMID26061753
PMCPMC4489704
OpenAlexW571060166

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.